New Haven, CT, July 19, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine^® ER for chronic pruritic conditions, announced today that it has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations.

“I am excited to welcome Yann to our  executive leadership team,” said Jennifer L. Good, President and Chief Executive Officer of Trevi. “Trevi is advancing its lead indication into pivotal trials and expanding its pipeline into new indications where we believe Nalbuphine ER’s unique mechanism of action could be effective. Yann’s extensive experience in commercial strategy, marketing and market access in the U.S., Europe and Latin America will prove to be valuable at this important time of growth for the Company.”

With over two decades of commercial and general management experience in the biopharmaceutical industry, Mr. Mazabraud  joins Trevi from an extensive career at Sanofi Genzyme where he most recently served as U.S. General Manager and North America Head, Rare Diseases. Mr. Mazabraud has held multiple leadership positions while at Sanofi Genzyme including Vice President and Head of Latin America. In his most recent roles, he reported to the CEO and was a member of the Sanofi Genzyme Executive Leadership Team. Mr. Mazabraud holds a Masters in Management from Ecole Supérieure de Commerce de La Rochelle.

“Trevi has a unique therapeutic platform with the potential to bring new and transformative therapies to patients affected by severe diseases with currently no options,” said Mr. Mazabraud. “I’m thrilled to join a passionate team that is working relentlessly for the benefit of thousands of patients worldwide, and I look forward to contributing to Trevi’s future growth and continued success.”

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing Nalbuphine ER for chronic pruritic conditions. Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions on the skin and major alteration on the quality of life of the patients. There are no approved therapies in the US or EU for this condition.

Nalbuphine ER is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. Because of Nalbuphine ER’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the Company believes Nalbuphine ER can have broad utility in treating chronic pruritus.

Founded in 2011, Trevi is headquartered in New Haven, CT. For additional information, visit www.trevitherapeutics.com.

# # #

Media contact: 
Laura Brophy
(203) 331-7618
email hidden; JavaScript is required